Peter Rahmer Sells 11,684 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Peter Rahmer sold 11,684 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the completion of the sale, the insider directly owned 277,964 shares in the company, valued at $2,118,085.68. This represents a 4.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Peter Rahmer also recently made the following trade(s):

• On Wednesday, January 28th, Peter Rahmer sold 1,354 shares of Relay Therapeutics stock. The stock was sold at an average price of $8.45, for a total value of $11,441.30.

Relay Therapeutics Price Performance

Shares of RLAY traded up $0.06 during midday trading on Thursday, hitting $7.71. The stock had a trading volume of 1,788,553 shares, compared to its average volume of 2,246,533. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -4.41 and a beta of 1.55. The company has a 50 day simple moving average of $7.93 and a two-hundred day simple moving average of $5.93. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $9.04.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.04). Analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on RLAY. Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Wells Fargo & Company upgraded Relay Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $13.00 in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

Institutional Trading of Relay Therapeutics

Several institutional investors have recently added to or reduced their stakes in RLAY. AQR Capital Management LLC increased its position in shares of Relay Therapeutics by 11.9% in the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after purchasing an additional 38,812 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Relay Therapeutics by 6.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock valued at $221,000 after buying an additional 5,238 shares during the period. Millennium Management LLC increased its holdings in Relay Therapeutics by 14.6% in the 1st quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after buying an additional 374,491 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in shares of Relay Therapeutics in the 1st quarter valued at approximately $53,000. Finally, Woodline Partners LP lifted its holdings in shares of Relay Therapeutics by 448.4% during the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after acquiring an additional 1,241,657 shares during the period. 96.98% of the stock is currently owned by institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.